Most uterine cancers have excellent five-year survival rates – up to 95% for localized cancer. Serous uterine cancer is an exception, with five-year survival rates of 35% to 50% for stage 1 or 2 ...

Scientists at The University of Texas at El Paso have found a promising new target in the fight against high-grade serous carcinoma, an aggressive form of ovarian cancer. Less than 50 percent of women ...

Researchers have identified the origin of ovarian cancer that develops in the fallopian tube, which opens doors to discovering new methods for diagnosing the disease and potential therapies. The ...

More than two-thirds of deaths from ovarian cancer are attributable to high-grade serous carcinoma. In one particularly aggressive form, only a small number of inactive immune cells can be found near ...

Researchers say that in the course of developing a new model for ovarian cancer, they've developed additional evidence that serous uterine cancer possibly begins in the fallopian tubes, not the uterus ...

Avutometinib and defactinib target KRAS-mutated recurrent low-grade serous ovarian cancer, potentially becoming the first FDA-approved treatment for this specific cancer type. The NDA is supported by ...

Opportunistic salpingectomy (OS) is feasible but not performed in almost a quarter of patients later diagnosed with high-grade serous carcinoma (HGSC), and about 40% of patients with a first-degree ...

A new study explains the genetic underpinnings of a rare and aggressive form of ovarian cancer—and offers a potential pathway for new treatments. High-grade serous carcinoma, the most common type of ...